Moderna, Inc. (MRNA) stock plummeted 6.26% on Monday during intraday trading, following the company's disappointing international revenue performance in the fourth quarter of 2024.
The biotechnology company reported total revenue of $966 million for the quarter, marking a significant 65.6% decline from the prior-year period. While Moderna's revenue from Europe exceeded expectations, contributing $292 million (30.23% of total revenue), its performance in the rest of world markets fell short of analysts' projections.
Revenue from the rest of world region totaled $397 million (41.10% of total revenue), missing Wall Street estimates by 27.97%. This lackluster performance, coupled with analysts' projections of further revenue declines in 2025, likely contributed to Moderna's stock plunge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.